Omnicell (NASDAQ:OMCL) Cut to Buy at Wall Street Zen

Wall Street Zen cut shares of Omnicell (NASDAQ:OMCL) from a strong-buy rating to a buy rating in a research report report published on Saturday morning,Wall Street Zen reports.

OMCL has been the topic of a number of other research reports. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. KeyCorp reiterated an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Wells Fargo & Company lowered their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Finally, Zacks Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $57.86.

Omnicell Trading Up 0.0%

Shares of NASDAQ OMCL opened at $37.35 on Friday. The company’s fifty day moving average is $35.02 and its 200-day moving average is $38.72. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of 38.91, a P/E/G ratio of 0.98 and a beta of 0.88. Omnicell has a twelve month low of $31.75 and a twelve month high of $55.00. The company has a quick ratio of 1.45, a current ratio of 1.65 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The company had revenue of $307.85 million during the quarter, compared to analyst estimates of $304.44 million. During the same quarter in the previous year, the business earned $0.51 EPS. The firm’s revenue was down .9% on a year-over-year basis. Equities research analysts predict that Omnicell will post 1.64 EPS for the current year.

Institutional Trading of Omnicell

Several hedge funds and other institutional investors have recently modified their holdings of OMCL. BlackRock Inc. bought a new stake in shares of Omnicell in the second quarter valued at about $313,044,000. Dimensional Fund Advisors LP boosted its position in shares of Omnicell by 6.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after buying an additional 137,834 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Omnicell by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock worth $47,095,000 after buying an additional 27,497 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Omnicell by 31.3% during the first quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock worth $19,390,000 after buying an additional 138,537 shares in the last quarter. Finally, First Light Asset Management LLC acquired a new stake in Omnicell in the 1st quarter valued at approximately $16,351,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings.

The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.

Founded in 1992, Omnicell serves customers in the United States and internationally.